Sumitomo Dainippon Pharma Oncology, a clinical-stage pharmaceutical company focused on research and development for novel cancer therapeutics, today announced the appointment of Jatin J. Shah, M.D. as Executive Vice President, Chief Medical Officer and Global Head of Development. In this new position Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline.

"Dr. Shah brings significant industry and clinical oncology experience, which is well-aligned with our future growth and success priorities," said Patricia S. Andrews, Chief Executive Officer, Global Head of Oncology, Sumitomo Dainippon Pharma Oncology (SDP Oncology). "We are pleased to have such an accomplished physician and researcher join us in our mission to discover and develop meaningful treatments for patients with cancer."

Dr. Shah brings over 20 years of medical and industry experience to SDP Oncology. Most recently, he served as Chief Medical Officer and Executive Vice President at Karyopharm Therapeutics where he led clinical research efforts that resulted in three successful sNDAs, multiple IND submissions and the development of a comprehensive solid tumor and hematological pipeline. At the University of Texas MD Anderson Cancer Center, Dr. Shah was an Associate Professor and Associate Program Director of the Malignant Hematology Fellowship, as well as Director of Myeloma Clinical and Translational Research in the Department of Lymphoma/Myeloma, Division of Cancer Medicine.

"I am excited to join the talented team at SDP Oncology and work with researchers and scientists who share a commitment to patients with cancer," said Jatin J. Shah, M.D. "I look forward to contributing to the next phase of SDP Oncology's growth as we work to address unmet needs in oncology and advance the development of our clinical and pre-clinical assets."